Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia.

European journal of clinical pharmacology - 23 Dec 2025

Sechaud Romain, Peters Thomas, Gu Helen, Rahmanzadeh Gholamreza, Sharma Gopal Krishna, Guichard Nathalie, Menssen Hans D

Abstract excerpt

PURPOSE: Midostaurin is predominantly metabolized by cytochrome P450 (CYP) 3A4 to form two active metabolites, CGP62221 and CGP52421. The current analysis from UNIFY, a randomized, double-blind, phase 3 study, investigated the impact of genetic polymorphism of CYP3A4/CYP3A5 on the exposure of midostaurin and its active metabolites, and on treatment-related toxicity in patients with FLT3-mutation-negative acute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Polymorphism, Genetic

Share to Staurosporine

Share to Young Adult

Source

Identifiers

PMID: 41432755
DOI: 10.1007/s00228-025-03971-y

Genes

CYP3A4
CYP3A5
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia.PMID 41432755Read ↗

Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Semantic proximity Read ↗

Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).Semantic proximity Read ↗

Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.Semantic proximity Read ↗

Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.Semantic proximity Read ↗

Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.Semantic proximity Read ↗

Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.Semantic proximity Read ↗

Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.Semantic proximity Read ↗

Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.Semantic proximity Read ↗

Midostaurin approved for FLT3-mutated AML.Semantic proximity Read ↗

Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.